We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 13 JUNE 2012
The "Lead Compound" Approach To Obviousness And Obviousness-Type Double Patenting
Foley & Lardner LLP
In Otsuka Pharmaceutical Co. v. Sandoz, Inc., the Federal Circuit upheld the district court’s determination that the claims at issue were neither obvious nor invalid under the doctrine of obviousness-type double patenting based on a "lead compound" approach to the obviousness determinations.
United StatesIntellectual Property











